fda status bpc-157 tb-500 2024 or 2025 Evidence out, ideology in. The FDA's quiet peptide pivot has nothing to do with the data and everything to do with whose side the regulator is choosing. On April 15, 2026, the RFK Jr., the FDA, and
Description
The clinic gave me silver sulfadiazine cream and told me to expect scarring
NAD + and precursors supplementation NAD + can be directly supplemented intravenously to increase cellular NAD + levels, which has been observed in healthy and elderly cohorts, suggesting improvements in cognitive function and increased expression of antioxidant genes, although these trials were conducted in small cohorts 66,116,117
doi: 10.1038/sj.npp.1301133
publicly addressed FDA action on a group of peptide substances that had been on the FDAs Category 2 restricted compounding list
